Previous studies with saccharide-protein conjugates have demonstrated that antibody responses to the saccharide can be improved by the preexistence of carrier immunity. Here we report that prior exposure to the carrier prptein can either enhance or suppress antibody response to polysaccharides administered in saccharide-protein conjugates. A dose-dependent role for carrier priming in the antisaccharide antibody response to three saccharide-protein conjugate vaccines, i.e., a Streptococcus pneumoniae type 4 polysaccharide-tetanus toxoid (TT) conjugate (PS4TT), a Neisseria meningitidis group C polysaccharide-TT conjugate (MenCTT), and a N. meningitWidis group C oligosaccharide-diphtheria mutant toxin conjugate (MenCCRM), was investigated. The results showed that an increase in the antipolysaccharide antibody response could be obtained for both PS4TT and MenCTT but not for MenCCRM with low-dose carrier priming (0.025 to 0.25 ,ug). However, suppression of the antipolysaccharide antibody response was observed with the PS4TT and MenCTT vaccines wi,h high-dose (25-,ug) carrier priming. There was no suppression effect with MenCCRM. The increase in the antipolysaccharide antibody response was shown to be restricted to the immunoglobulin Gl (IgGl) subclass, whereas suppression with high-dose carrier prining affected all antipolysaccharide subclass antibodies induced by PS4TT (IgGl, IgG2b, and IgG3) and only two of the four subclass antibodies induced by MenCTT (IgG2a and IgG2b). The increase in the antipolysaccharide antibody response was also present at the antipolysaccharide IgM antibody level but was not observed at the anti-carrier IgG antibody level.
The enhancement of the immunogenicity of polysaccharides by coupling polysaccharides or oligosaccharides to proteins has been amply demonstrated (1, 2, 4, 7, 9, 14) . In most cases, saccharides have been coupled to large immunogenic proteins such as tetanus toxoid (TT) or diphtheria toxoid (DT). These proteins are chosen in most studies because both have been employed for human vaccination for many years without untoward side effects. Moreover, since most individuals are immunized with TT and DT, the response against a hapten coupled to carriers like TT and DT potentially can be improved by the preexistence of anticarrier immunity. However, the antibody response to a hapten coupled to the carrier protein can also be inhibited when the recipient has been previously immunized with the unmodified protein. This phenomenon has been termed carrierinduced epitope suppression (17) and was recently demonstrated to occur with a number of synthetic peptide-protein conjugates (10, 19, 20, 27, 28, 31) . In humans, carrierinduced epitope suppression has been described for synthetic peptides coupled to TT (10, 14) . Several investigators suggested that epitope suppression could also occur upon vaccination with saccharide-protein conjugate vaccines in human adults (7, 8, 16 ), but experimental evidence was not given. Carrier priming with one dose of carrier protein has been shown to have a positive effect on the polysaccharide response (8, 16) .
The application of saccharide-protein conjugates is of primary importance in inducing protective immunity against infection with several encapsulated bacteria in infants and in elderly and immunodeficient patients. Therefore, we investigated in an animal model the role of carrier priming on the antibody response to a saccharide-protein conjugate. Since different saccharides can be coupled to TT, it is important to know whether the influence of carrier priming is similar with different saccharides when TT is used as a carrier. We found that preimmunization with low doses of TT enhanced the antibody response to Streptococcus pneumoniae type 4 polysaccharide (PS4) and meningococcal group C (MenC) polysaccharide upon vaccination with TT conjugates of these polysaccharides. High doses of carrier priming, however, inhibited a conjugate-induced antipolysaccharide antibody response. Carrier priming with DT did not affect an antibody response to a MenC oligosaccharide-mutant DT (CRM197) conjugate (MenCCRM197).
MATERIALS AND METHODS
Animals. One-week-old male and female and 8-to 12-week-old female NIH/RIVM mice (random outbred strain) were used. They were bred and kept at the National Institute of Public Health and Environmental Protection.
Antigens. In this study, three different saccharide-protein conjugates were used. A polysaccharide-TT conjugate of S. pneumoniae type 4 (PS4TT) with a polysaccharide protein ratio of 0.7:1 (wt/wt) was prepared by using the carbodiimide coupling procedure as described earlier (21) . In brief, PS4 was activated with cyanogen bromide and subsequently coupled to a spacer 6-aminohexanoic acid. The purified product of this reaction was coupled to TT by using 1-ethyl-3(3-dimethylaminopropyl)carbodiimide. Polysaccharideprotein conjugates were purified by gel filtration on a Sepharose CL-4B column. The second polysaccharide-protein conjugate used was a conjugate of MenC and TT (MenCTT) with a polysaccharide/protein ratio of 1:1 (wt/wt). The conjugate was prepared by using methods similar to those described above for PS4TT (4) .
In addition, an experimental oligosaccharide-mutant DT conjugate (CRM197) vaccine of Neisseria meningitidis group C (MenCCRM) was used. Oligosaccharides of MenC polysaccharide, obtained by mild periodate oxidation, were coupled to CRM197 with a saccharide-to-protein ratio of 1:2.5 by using reductive amination (2) .
TT and DT were purchased from the National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands.
Immunization scheme. Groups of 8 to 10 mice were immunized subcutaneously (s.c.) with 0.1-ml solutions of variable doses (ranging from 0.025 to 25 pig) of TT or DT in 0.9% NaCl. A s.c. second immunization with the saccharideprotein conjugate containing 0.5 pLg of saccharide was given 42 days after carrier priming. Neonatal mice were primed with variable doses of TT at 1 week of age and were immunized with 0.5 ,ug of conjugate (containing 0.5 p,g of saccharide) at days 28 and 56 after carrier priming. Blood samples were obtained from the tail veins at various times after immunization with the conjugate. Sera were stored at -20°C until use.
Antibody titers. Antibody titers against MenC polysaccharide, PS4, TT, and DT were determined by enzyme-linked immunosorbent assay as described below.
Wells of highly activated immunoassay microplates (Flow, Irvine, United Kingdom) were coated with rabbit anti-PS4 antibodies (State Serum Institute, Copenhagen, Denmark) in 0.05 M carbonate buffer (pH 9.6). After incubation for 3 h at 37°C, plates were washed and incubated overnight at 4°C with 1 pig of PS4 (American Type Culture Collection, Rockville, Md.) per ml in 0.9% NaCl. For the detection of anti-MenC polysaccharide antibodies, microplates were coated with sheep antibodies to MenC polysaccharide (10 pig/ml) (3) Plates were washed and incubated with the phosphatase substrate p-nitrophenylphosphate (Sigma, St. Louis, Mo.) at a concentration of 1 mg/ml in 10% diethanolamine buffer (pH 9.8). After 30 to 60 min of incubation at room temperature, the reaction was stopped by the addition of 50 pil of 2.4 N NaOH and the A405 was read by using a Titertek Multiscan ELISA reader (Flow). All antibody titers were expressed as percentages of a hyperimmune serum either for PS4 or MenC polysaccharide or for TT or DT.
To exclude interference by antipneumococcal cell wall polysaccharide antibodies in the determination of IgM anti-PS4 antibodies, all sera were adsorbed with soluble cell wall polysaccharide (CPs; State Serum Institute). To that end, soluble cell wall polysaccharide at a concentration of 250 ,ug/ml was added to the dilution buffer during serum incubation as described in detail elsewhere (22) .
Statistical analysis. Results are expressed as logarithmic mean titers of n independent observations + standard deviation. Geometric mean (antilog) titers are expressed in parentheses. Significance was tested by a one-way or twoway analysis of variance. Dunnett's correction (12) was used to compare the different treatment groups with the control group.
RESULTS
Effect of preimmunization with carrier on antibody responses to polysaccharide-protein conjugates in adult mice. In order to investigate the dose dependency as well as the specificity of carrier priming, animals were immunized with various amounts (0.025 to 25 pig) of carrier protein (TT or DT). Six weeks later, animals were immunized with 0.5 pig of a saccharide-protein conjugate. Anti-polysaccharide IgG antibodies as measured on day 21 after immunization with the conjugate are shown in Table 1 . Mice which were preimmunized with a low dose of carrier protein (0.025 pig of TT) before administration of the polysaccharide-protein conjugates (MenCTT or PS4TT) had antipolysaccharide antibodies higher than those of mice injected with saline or an irrelevant carrier protein (DT). This effect was statistically significant for mice immunized with MenCTT (P < 0.01) after carrier priming but not for mice immunized with PS4TT after carrier priming. When mice were primed with a high dose of carrier protein (25 pig) before immunization with the polysaccharide-protein conjugates, the antipolysaccharide antibody response was suppressed, unlike the response in mice primed with a high dose of irrelevant protein or saline. In mice immunized with PS4TT, the lower anti-PS4 antibody response was statistically significant (P < 0.01). Mice immunized with MenCTT after being primed with 25 pig of TT showed a tetidency to a lower antipolysaccharide antibody response; however, differences from their respective controls were not significant. In contrast to results with the polysaccharide-TT conjugates, no effect of carrier priming on the antipolysaccharide IgG antibody response induced by the oligosaccharide-protein conjugate vaccine MenCCRM could be observed after priming at any dose level of DT. Anti-TT IgG antibody responses in mice primed with 25 pig of TT and reimmunized with PS4TT did not differ from those of mice primed with 2.5 pig of TT (Fig. 1) . Either low-or high-dose carrier priming enhanced the anti-PS4 IgM antibody response (P < 0.01) but did not affect anti-MenC polysaccharide IgM antibody responses ( Table 2 ). The inhibiting effect of high-dose (25-pig) carrier priming was thus limited to the antipolysaccharide IgG antibody response.
Effect of preimmunization with carrier on antibody responses to a polysaccharide-protein conjugate in neonatal mice. Of interest is whether the effects in neonatal mice of carrier priming on the polysaccharide antibody response, when the polysaccharide is administered as part of a polysaccharide-protein conjugate, are similar to the effects conjugate-induced anti-PS4 antibody response by both the IgM and IgG isotypes (Fig. 2) . High-dose carrier priming resulted in suppression of the conjugate-induced anti-PS4 IgG antibody response. The phenomena of enhancement and inhibition of anti-PS4 antibody formation after carrier priming therefore were operative in both adult and neonatal mice. Neonatal mice were immunized a second time with PS4TT at 9 weeks of age, and this immunization resulted in an 8.4-fold increase in anti-PS4 IgG antibodies in low-dose (0.025-,ug)-carrier-primed mice. In nonprimed animals, the anti-PS4 IgG antibody response increased only 3.6-fold upon a second immunization with PS4TT (Fig. 2) . In high-dose-carrierprimed mice, no increase in either PS4 IgM or PS4 IgG antibodies could be observed upon secondary immunization with the conjugate (Fig. 2) . The consequences of carrier priming thus remained clear even after repeated immunization with the conjugate vaccines. Statistical analysis of data from both neonatal and adult mice showed a significant increase in the anti-PS4 IgG antibody response (P < 0.01) of low-dose-carrier-primed mice reimmunized with the conjugate and a significant decrease (P < 0.05) in the anti-PS4 IgG response of high-dose-carrier-primed mice reimmunized with the conjugate.
Influence of TT priming on IgG subclass distribution of antipolysaccharide antibodies. Preimmunization with TT may also influence the IgG subclass distribution of the antipolysaccharide antibody response. Results in Table 3 show that upon low-dose carrier priming, the increased levels of anti-MenC polysaccharide IgG antibodies were mainly due to an increase in the IgGl subclass (P < 0.01). The IgG2b subclass increased to a lesser extent (P < 0.05), whereas the IgG3 antibody level was significantly decreased (P < 0.05). No effect on the IgG2a antibody level was observed with low-dose carrier priming. The increase in IgGl antibodies was also observed with PS4TT but not with the oligosaccharide-protein conjugate MenCCRM. High-dose carrier priming showed suppression of all IgG subclasses (IgGl, IgG2b, and IgG3) (P < 0.05) with the PS4TT vaccine, whereas suppression of the antipolysaccharide immune response to MenCTT (which induces IgGl, IgG2a, IgG2b, and IgG3 antibodies) was evident only for the IgG2a (P < 0.01) and IgG2b antibodies. No effect of high-dose carrier priming was observed with the oligosaccharide-protein conjugate vaccine which induced predominantly antipolysaccharide antibodies of the IgGl subclass.
In neonatal mice, the effects of low-and high-dose carrier priming on the antipolysaccharide IgG subclass distribution upon immunization with the PS4TT vaccine were similar to those found in adult mice (data not shown). (6, 25) . Enhancement of the antipolysaccharide antibody response was observed in our studies by low-dose carrier priming for PS4TT and MenCTT. It was observed that low-dose carrier priming especially increased IgGl and IgG2b antipolysaccharide antibodies. Since both IgGl and IgG2b (IgGl > > IgG2b) are subclasses restricted to a typical T-cell-dependent antibody response in mice (29) , it might be suggested that an increase in carrier-specific T-cell help resulted in a more T-celldependent antibody response. Antibodies of the IgG3 subclass are predominantly induced in an immune response to T-cell-independent type 2 antigens (such as polysaccharides) and were found in minor quantities upon vaccination with PS4TT and MenCTT. Antibodies of this subclass were observed to be decreased after low-dose carrier priming and subsequent vaccination with MenCTT. This might indicate that the antipolysaccharide antibody response indeed switched to a more T-cell-dependent character. Remarkable was that the doses of TT used for priming that caused enhancement of the antipolysaccharide response induced by TT-conjugated polysaccharide did not induce detectable anti-TT antibody levels after primary immunization (Fig. 1) . Increasing the priming dose of carrier to 2.5 ,ug per animal, which results in detectable anti-TT antibodies, abrogated the positive effect of carrier priming on the antipolysaccharide antibody response. In contrast to earlier observations, we were able to show that using a high dose of TT (25 jig (8) that the use of high-dose carrier priming led to antihapten antibody responses with a T-cell-independent character. Since most polysaccharides are T-cell-independent type 2 antigens, the T-cell-independent character of the antipolysaccharide antibody response under epitope-suppressed conditions should be very clear in this study. However, analysis of the antipolysaccharide IgG subclass distribution showed that all three subclasses (IgGl, IgG2b, and IgG3) which could be induced by PS4TT were suppressed upon high-dose carrier priming. With MenCTT, only IgG2a and IgG2b of the four contributing subclasses (IgGl, IgG2a, IgG2b, and IgG3) were significantly suppressed. The observation that only IgG2a and IgG2b were suppressed by high-dose carrier priming was reported earlier by Herzenberg et al. (17, 18) . Our data do not support the hypothesis that the hapten behaves as a T-cell-independent antigen, since the IgG3 subclass, the antibody subclass preferentially induced by T-cell-independent antigens, would not be influenced by high-dose carrier priming. No indication for either low-dose-carrier-induced enhancement or high-dose-carrierinduced inhibition of the antipolysaccharide antibody response could be observed when a DT-MenCCRM combination was used. In contrast to results in the study by Vella other studies in which the influence of high-dose DT priming on the antibody response to a peptide-DT or a saccharideprotein conjugate was reported (1, 14) . In one study, DT also failed to induce epitope suppression, whereas when TT was used as a carrier protein to the same peptide, suppression was induced (14) . In the study by Anderson (1), an improved antipolysaccharide antibody response occurred upon vaccination with the H. influenzae type b oligosaccharide-mutant DT conjugate in rabbits primed with 100 ,ug of carrier protein on aluminum phosphate adjuvant compared with nonprimed animals.
In this study, we have used two TT-polysaccharide conjugates and one CRM197-oligosaccharide conjugate, which is apart from carrier protein and is also constructed differently from the two TT conjugates. Therefore, variables such as the nature of the polysaccharide, the protein/polysaccharide ratio, and unidentified factors related to the particular construction and shape may have contributed to the inhibitory effects observed. No general rule on the effects of carrier priming can therefore be deduced from these experiments. The data do indicate, however, that high-dose carrier priming may cause significant suppressive effects on the antipolysaccharide IgG antibody response induced by conjugated polysaccharide.
The mechanism responsible for suppression of the antihapten antibody response to hapten-carrier conjugates upon high-dose carrier priming is still unclear. Involvement of both T suppressor cells (13, 17-19, 27, 28) and carrierspecific B memory cells (13, 19, 27, 28) has been reported. Herzenberg et al. (17, 18) postulated activation of T suppressor cells. Schutze et al. (27, 28) showed the involvement of B memory cells in the phenomenon of epitope suppression. They argue that because of prior immunization with the carrier protein, a predominance of carrier-specific B-cell clones exists that competitively decreases the interaction between hapten-specific B cells and the hapten at the time of conjugate immunization. Another possible explanation might be that circulating antibodies against the carrier protein are responsible for scavenging of the antigen or the formation of immune complexes which inhibit the immune response.
Recent studies with H. influenzae type b polysaccharideor oligosaccharide-protein conjugates show that these conjugate vaccines are highly efficacious in preventing H. influenzae type b disease in infants and young children (32) .
These conjugate vaccines as well as new conjugate vaccines under development will therefore be used on a wide scale in the near future in order to protect children against infections by several encapsulated bacteria. In most cases, DT or TT will be used as the carrier protein in the conjugate vaccine. Because of the growing emphasis on TT immunizations in different health programs, it is important to be aware of a potential negative effect of the vaccination status of humans in their response to those conjugate vaccines. However, extrapolation of our observed data to the human situation should be made cautiously for several reasons. First, the induction of epitope suppression in mice required relatively high doses of carrier protein relative to body weight (25 ,ug per animal), since only 10 to 15 ,ug is used for immunizations in humans. However, we do not know whether sensitization by repeated injections with lower doses of TT can also induce epitope suppression. Second, in our study, mice were immunized only with TT, whereas in humans, TT is administered together with diphtheria, pertussis, and polio vaccines in a combination vaccine. Two studies in mice have shown that the use of Bordetella pertussis vaccine and its adjuvant components can modulate immune suppression (17, 31) . Thus, it is possible that the pertussis component in the combination vaccine diminishes the potential for TT to cause epitope suppression in humans. Clearly, more studies are needed to address the effect of carrier priming on the outcome of saccharide-protein conjugate vaccinations as well as to develop different ways of circumventing epitope suppression.
